Sfoglia per AUTORE
ANTONUZZO L
Collezione ASL Biella

  

Items : 5

Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study. in Targeted oncology / Target Oncol. 2024 May;19(3):359-370. doi: 10.1007/s11523-024-01060-1. Epub 2024 May 1.

2024
ASL Biella
AOU Città della Salute di Torino

Stefano C; Rimassa L; Casadei-Gardini A; Antonuzzo L; Vivaldi C; Rizzato MD; Foti S; De Braud F; De Rosa A; Ratti F; Aldrighetti L; Fornaro L; Niger M; Zanuso V; Garattini SK; Satolli MA; Rossari F; Brandi G; Brunetti O; Leone F; Pirrone C; Diana A; Toma I; Pretta A; Lorenzo A; Landriscina M; Gusmaroli E; Bergamo F; Balsano R; et alii...

Prognostic and predictive role of FGFR2 and IDH1 targetable alterations in advanced biliary tract cancer (aBTC): Data from the Italian ANITA dataset in Annals of Oncology

2024
ASL Biella

Genovesi V; Rimini M; Pressiani T; Soldà C; Nichetti F; Salvatore L; Antonuzzo L; Silvestro L; Diana A; Leone F; Foti S; Balsano R; Piva VM; Pircher CC; Camera S; Masi G; Rimassa L; De Grandis MC; Gardini AC; Fornaro L;

Extended molecular profiling (EMP) and access to targeted treatment (TT) in advanced biliary tract cancer (BTC): Results from the Italian cholangiocarcinoma dataset (ANITA) in Annals of Oncology

2024
ASL Biella

Genovesi V; Rimini M; Pressiani T; Rizzato MD; Niger M; Salvatore L; Antonuzzo L; Silvestro L; Diana A; Leone F; Salani F; Foti S; Zanuso V; De Rosa A; Pircher CC; Vivaldi C; Rimassa L; Sperotto S; Casadei Gardini A; Fornaro L;

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. in British journal of cancer / Br J Cancer. 2017 Jan;116(3):318-323. doi: 10.1038/bjc.2016.413. Epub 2017 Jan 12.

2017
ASL Biella
AO Cuneo

Cremolini C; Falcone A; Boni L; Tomcikova D; Paris M; Bonetti A; Martignetti A; Dargenio F; Miraglio E; Amoroso D; Banzi MC; Borelli B; Chiara S; Loupakis F; Masi G; Allegrini G; Barbara C; Salvatore L; Antonuzzo L; Marmorino F;

Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study in Journal of Clinical Oncology

2016
ASL Biella

Marmorino F; Cremolini C; Loupakis F; Barbara C; Dargenio F; Miraglio E; Masi G; Salvatore L; Marcucci L; Antonuzzo L; Chiara S; Banzi C; Schirripa M; Amoroso D; Bonetti A; Martignetti A; Paris M; Boni L; Tomcikova D; Falcone A;